Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cabo Verde
Cameroon
Central African Republic
Chad
Comoros
Congo
Cote D Ivoire
Democratic Republic Of The Congo
Equatorial Guinea
Eritrea
Eswatini
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mayotte
Mozambique
Namibia
Niger
Nigeria
Reunion
Rwanda
Sao Tome And Principe
Senegal
Seychelles
Sierra Leone
South Africa
South Sudan
Swaziland
Togo
Uganda
United Republic Of Tanzania
Zambia
Zimbabwe
Anguilla
Antigua And Barbuda
Argentina
Aruba
Barbados
Belize
Bermuda
Bolivia Plurinational State Of
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
Colombia
Costa Rica
Cuba
Dominica
Dominican Republic
Ecuador
El Salvador
Falkland Islands Malvinas
French Guiana
Grenada
Guadeloupe
Guatemala
Guyana
Haiti
Honduras
Jamaica
Martinique
Mexico
Montserrat
Netherlands Antilles
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Helena
Saint Kitts And Nevis
Saint Lucia
Saint Pierre And Miquelon
Saint Vincent And The Grenadines
St Eustatius
Suriname
The Bahamas
Trinidad And Tobago
Turks And Caicos Islands
United States
United States Virgin Islands
Uruguay
Venezuela Bolivarian Republic Of
Bangladesh
Bhutan
India
Indonesia
Korea North
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor Leste
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia And Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Faroe Islands
Finland
France
Georgia
Germany
Gibraltar
Greece
Greenland
Hungary
Iceland
Ireland
Isle Of Man
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic Of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Svalbard And Jan Mayen Islands
Sweden
Switzerland
Tajikistan
The Former Yugoslav Republic Of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom Of Great Britain And Northern Ireland
Uzbekistan
Afghanistan
Bahrain
Djibouti
Egypt
Iran Islamic Republic Of
Iraq
Jordan
Kuwait
Lebanon
Libya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
State of Palestine
Sudan
Syrian Arab Republic
Tunisia
United Arab Emirates
West Bank And Gaza Strip
Western Sahara
Yemen
American Samoa
Australia
Brunei Darussalam
Cambodia
China
Christmas Island
Cocos Keeling Islands
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Korea South
Lao People S Democratic Republic
Laos
Malaysia
Marshall Islands
Micronesia Federated States Of
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Norfolk Island
Northern Mariana Islands
Palau
Papua New Guinea
Philippines
Pitcairn Island
Samoa
Singapore
Solomon Islands
Taiwan
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
Wallis And Futuna
Cholera
Covid-19
Dengue
Diphtheria
Ebola
Haemophilus influenzae
Hepatitis A
Hepatitis B
Hepatitis E
HIB
HIV-AIDS
Human papillomavirus
Influenza
Japanese encephalitis
Malaria
Measles
Meningococcal meningitis
Mumps
Pertussis
Pneumococcal disease
Polio
Rabies
Rotavirus
Rubella
Smallpox
Tetanus
Tick-borne encephalitis
Tuberculosis
Typhoid
Varicella
Yellow fever
Zika
Bill & Melinda Gates Foundation
Gavi, the Vaccine Alliance
Global Vaccine Action Plan (GVAP)
Immunization Practices Advisory Committee (IPAC)
International Vaccine Access Center (IVAC)
JSI
MSF
PATH
People that Deliver (PtD)
Strategic Advisory Group of Experts on Immunization (SAGE)
TechNet-21
UNICEF
USAID
WHO
WHO Performance, Quality and Safety (PQS)
Browse thousands of immunization resources shared by TechNet members
Agenda - GVIRF 2014
KN2 Research for Universal Health Coverage; Perspective on Vaccines and Poverty Reduction
KN3 Importance of Innovation in Addressing Global Health Gaps in the Developing World
P2 Regulatory and Public Health Challenges for Vaccines Inducing Modest Efficacy
P3 Developing Next Generation Vaccines: Defining the Improvements Needed and Evaluating Their Potential
P5 Research to improve monitoring and evaluation of immunization programs
P6 Protection of pregnant women, neonates and infants by maternal immunization
P7 Innovative vaccine research: the point of view of industry and biotech companies
W1 Towards the Development of a Universal Influenza Vaccine
W2 Preferred Product Characteristics (PPC) as a Way to Guide Development of Products of High Public Health Utility
W4 How to Optimize Immunization Coverage? A case study from Measles-Rubella vaccination
W6 Innovation in vaccine delivery and presentation: How can technological advances increase program performance?
W7 Contributions of Regulatory Science to Vaccine Access
W8 Systems Vaccinology
KN1.3 GVIRF Overview and Goals
KN1.4 What do we expect from the meeting?
KN2.1 WHO Director-General address to GVIRF
KN2.2 Perspectives on Vaccines and Poverty Reduction
KN3-1 The Importance of Innovation in Addressing Global Health Gaps in the Developing World
P1a.1 Status of HIV Vaccine Research & Development
P1a.2 Progress towards the development of an HIV vaccine: Discussion
P1b.1 Update on Tuberculosis Vaccines - 2014
P1b.2 TB Vaccine Development: Challenges & Opportunities
P1c.1 Progress towards the development of a malaria vaccine
P1c.2 Progress towards the development of a malaria vaccine: discussion
P2.1 Regulatory and public health challenges
P2.2 Regulatory Considerations for Determining Vaccine Efficacy
P3.1 Developing next generation vaccines: Introduction
P3.2 Developing Country Vaccine Manufacturers - Access to Immunization
P3.3 Developing Next Generation Rotavirus Vaccines: Prospects from the Pipeline to Address Remaining Public Health Needs
P3.4 Evaluation of the Next Generation of Rotavirus Vaccines
P5.1 Immunization Registries in Latin America and the Caribbean
P5.2 Influenza Vaccine Use in the Americas: Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-1
P6.1 Public Health Benefits of Maternal Immunization
P6.2 Maternal Immunization: which impact on infant immunity?
P7.1 Innovation for vaccines against poverty diseases: the need for new support mechanisms
W1.1 Towards the Development of a Universal Influenza Vaccine
W2.1 WHO Preferred Product Characteristics: Bridging Vaccine R&D with Public Health
W2.2 RSV Vaccine Development for Low and Middle Income Countries: Challenges and Progress
W2.3 Group A streptococcal vaccines: Challenges and progress
W3.2 Pre-exposure rabies vaccination (PreP) in children of endemic countries
W4.1 Progress, Challenges, and Lessons Learned in Achieving Measles and Rubella Goals
W4.2 Prioritizing the Research Agenda for Measles and Rubella
W5.1 Immunization implementation research priority setting
W5.2 Factors influencing community health volunteers in participating in health programs in Africa
W5.3 Strengthening national capacity for evidence-based immunization policy: the case of program costing in Honduras
W5.4 Building Implementation Research Capacity for Polio Eradication
W6.1 WHO - Next-generation Vaccine Delivery Technology Meeting Summary
W6.2 Beyond the cold chain… Meningitis A conjugate vaccine in a controlled temperature chain: Experience from Benin
W6.3 Case Study: The Uniject Injection System
W7.1 Contributions of Regulatory Science to Vaccine Access
W7.2 Enhancement in Laboratory Research to Support Innovations in Regulatory Science for the Evaluation of New Vaccines
W7.3 How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines?
W8.1 How can recent technological advances in systems vaccinology accelerate next-generation vaccine development?
W8.2 Systems Vaccinology
W8.3 Application of technological advances to clinical trials
P8 General Conclusion
*Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery
KN1.2 R&D in the "Decade of Vaccines"
KN1 Opening Session and Keynote
KN1.1 Vaccine Research and Development: Challenges and Opportunities
P1c Develop New and Improved Vaccines - Malaria
P1b Develop New and Improved Vaccines - TB
Workshop presentation